Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Multicenter Adherence Study of Asthma Medication for Children in Korea.

Kim CK, Callaway Z, Choi J, Kim HB, Kwon EM, Chang YS, Rha YH, Hong SJ, Oh JW, Kim HH, Lim DH, Kim SW, Park KS, Cho YH, Chung HL, Park HJ, Jung SG, Kang IJ, Hyun MC, Oh MY, Jung JA, Kim MS, Shim JY, Kim JT, Koh YY; KAPARD Work Group on Asthma Medication Compliance.

Allergy Asthma Immunol Res. 2019 Mar;11(2):222-230. doi: 10.4168/aair.2019.11.2.222.

2.

Potential ecotoxicological effects of elevated bicarbonate ion concentrations on marine organisms.

Gim BM, Hong S, Lee JS, Kim NH, Kwon EM, Gil JW, Lim HH, Jeon EC, Khim JS.

Environ Pollut. 2018 Oct;241:194-199. doi: 10.1016/j.envpol.2018.05.057. Epub 2018 May 25.

PMID:
29807279
3.

Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.

Zhen T, Kwon EM, Zhao L, Hsu J, Hyde RK, Lu Y, Alemu L, Speck NA, Liu PP.

Blood. 2017 Nov 30;130(22):2431-2442. doi: 10.1182/blood-2017-04-780106. Epub 2017 Oct 10.

4.

The C-terminal multimerization domain is essential for leukemia development by CBFβ-SMMHC in a mouse knockin model.

Zhao L, Alkadi H, Kwon EM, Zhen T, Lichtenberg J, Alemu L, Cheng J, Friedman AD, Liu PP.

Leukemia. 2017 Dec;31(12):2841-2844. doi: 10.1038/leu.2017.262. Epub 2017 Aug 18. No abstract available.

5.

iPSCs and fibroblast subclones from the same fibroblast population contain comparable levels of sequence variations.

Kwon EM, Connelly JP, Hansen NF, Donovan FX, Winkler T, Davis BW, Alkadi H, Chandrasekharappa SC, Dunbar CE, Mullikin JC, Liu P.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1964-1969. doi: 10.1073/pnas.1616035114. Epub 2017 Feb 6.

6.

Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.

Decker B, Parker HG, Dhawan D, Kwon EM, Karlins E, Davis BW, Ramos-Vara JA, Bonney PL, McNiel EA, Knapp DW, Ostrander EA.

Mol Cancer Res. 2015 Jun;13(6):993-1002. doi: 10.1158/1541-7786.MCR-14-0689. Epub 2015 Mar 12.

7.

Targeted correction of RUNX1 mutation in FPD patient-specific induced pluripotent stem cells rescues megakaryopoietic defects.

Connelly JP, Kwon EM, Gao Y, Trivedi NS, Elkahloun AG, Horwitz MS, Cheng L, Liu PP.

Blood. 2014 Sep 18;124(12):1926-30.

8.

Dexibuprofen for fever in children with upper respiratory tract infection.

Kim CK, Callaway Z, Choung JT, Yu JH, Shim KS, Kwon EM, Koh YY.

Pediatr Int. 2013 Aug;55(4):443-9. doi: 10.1111/ped.12125.

PMID:
23659181
9.

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.

Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA, Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D, Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL, English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R, Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A, Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P, Nordestgaard BG, Røder MA, Nielsen SF, Bojesen SE, Siddiq A, Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q, McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA, Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P, Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC; COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative; Australian Prostate Cancer Bioresource; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators; PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Kote-Jarai Z, Easton DF.

Nat Genet. 2013 Apr;45(4):385-91, 391e1-2. doi: 10.1038/ng.2560.

10.

Variation in selenoenzyme genes and prostate cancer risk and survival.

Geybels MS, Hutter CM, Kwon EM, Ostrander EA, Fu R, Feng Z, Stanford JL, Peters U.

Prostate. 2013 May;73(7):734-42. doi: 10.1002/pros.22617. Epub 2012 Nov 9.

11.

HOXB13 mutations in a population-based, case-control study of prostate cancer.

Stott-Miller M, Karyadi DM, Smith T, Kwon EM, Kolb S, Stanford JL, Ostrander EA.

Prostate. 2013 May;73(6):634-41. doi: 10.1002/pros.22604. Epub 2012 Nov 5.

12.

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.

Amin Al Olama A, Kote-Jarai Z, Schumacher FR, Wiklund F, Berndt SI, Benlloch S, Giles GG, Severi G, Neal DE, Hamdy FC, Donovan JL, Hunter DJ, Henderson BE, Thun MJ, Gaziano M, Giovannucci EL, Siddiq A, Travis RC, Cox DG, Canzian F, Riboli E, Key TJ, Andriole G, Albanes D, Hayes RB, Schleutker J, Auvinen A, Tammela TL, Weischer M, Stanford JL, Ostrander EA, Cybulski C, Lubinski J, Thibodeau SN, Schaid DJ, Sorensen KD, Batra J, Clements JA, Chambers S, Aitken J, Gardiner RA, Maier C, Vogel W, Dörk T, Brenner H, Habuchi T, Ingles S, John EM, Dickinson JL, Cannon-Albright L, Teixeira MR, Kaneva R, Zhang HW, Lu YJ, Park JY, Cooney KA, Muir KR, Leongamornlert DA, Saunders E, Tymrakiewicz M, Mahmud N, Guy M, Govindasami K, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Dudderidge T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English D, Virtamo J, Le Marchand L, Campa D, Kaaks R, Lindstrom S, Diver WR, Gapstur S, Yeager M, Cox A, Stern MC, Corral R, Aly M, Isaacs W, Adolfsson J, Xu J, Zheng SL, Wahlfors T, Taari K, Kujala P, Klarskov P, Nordestgaard BG, Røder MA, Frikke-Schmidt R, Bojesen SE, FitzGerald LM, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Rinckleb A, Luedeke M, Herkommer K, Meyer A, Serth J, Marthick JR, Patterson B, Wokolorczyk D, Spurdle A, Lose F, McDonnell SK, Joshi AD, Shahabi A, Pinto P, Santos J, Ray A, Sellers TA, Lin HY, Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; Australian Prostate Cancer Bioresource; PRACTICAL Consortium, Chanock S, Gronberg H, Haiman CA, Kraft P, Easton DF, Eeles RA.

Hum Mol Genet. 2013 Jan 15;22(2):408-15. doi: 10.1093/hmg/dds425. Epub 2012 Oct 12.

13.

Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.

FitzGerald LM, Zhang X, Kolb S, Kwon EM, Liew YC, Hurtado-Coll A, Knudsen BS, Ostrander EA, Stanford JL.

Hum Mutat. 2013 Jan;34(1):149-56. doi: 10.1002/humu.22176. Epub 2012 Oct 4.

14.

ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity.

Wu X, Ellmann S, Rubin E, Gil M, Jin K, Han L, Chen H, Kwon EM, Guo J, Ha HC, Sukumar S.

PLoS One. 2012;7(7):e40644. doi: 10.1371/journal.pone.0040644. Epub 2012 Jul 23.

15.

The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer.

Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, Cullen J, Abadie J, Kwon EM, Gröne A, Devauchelle P, Rimbault M, Karyadi DM, Lynch M, Galibert F, Breen M, Rutteman GR, André C, Parker HG, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1019-27. doi: 10.1158/1055-9965.EPI-12-0190-T. Epub 2012 May 23.

16.

Association of variants in estrogen-related pathway genes with prostate cancer risk.

Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA, Stanford JL.

Prostate. 2013 Jan;73(1):1-10. doi: 10.1002/pros.22534. Epub 2012 May 1.

17.

Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.

Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL, Ostrander EA.

Cancer Epidemiol. 2012 Aug;36(4):347-53. doi: 10.1016/j.canep.2012.04.002. Epub 2012 Apr 26.

18.

The monoamine oxidase A gene promoter repeat and prostate cancer risk.

White TA, Kwon EM, Fu R, Lucas JM, Ostrander EA, Stanford JL, Nelson PS.

Prostate. 2012 Nov;72(15):1622-7. doi: 10.1002/pros.22515. Epub 2012 Apr 2.

19.

Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development.

Hahn NM, Bonney PL, Dhawan D, Jones DR, Balch C, Guo Z, Hartman-Frey C, Fang F, Parker HG, Kwon EM, Ostrander EA, Nephew KP, Knapp DW.

J Urol. 2012 Jan;187(1):302-9. doi: 10.1016/j.juro.2011.09.010. Epub 2011 Nov 17.

20.

Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.

Lin DW, FitzGerald LM, Fu R, Kwon EM, Zheng SL, Kolb S, Wiklund F, Stattin P, Isaacs WB, Xu J, Ostrander EA, Feng Z, Grönberg H, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2011 Sep;20(9):1928-36. doi: 10.1158/1055-9965.EPI-11-0236. Epub 2011 Aug 16.

21.

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study.

Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, Campa D, Riboli E, Key T, Gronberg H, Hunter DJ, Kraft P, Thun MJ, Ingles S, Chanock S, Albanes D, Hayes RB, Neal DE, Hamdy FC, Donovan JL, Pharoah P, Schumacher F, Henderson BE, Stanford JL, Ostrander EA, Sorensen KD, Dörk T, Andriole G, Dickinson JL, Cybulski C, Lubinski J, Spurdle A, Clements JA, Chambers S, Aitken J, Gardiner RA, Thibodeau SN, Schaid D, John EM, Maier C, Vogel W, Cooney KA, Park JY, Cannon-Albright L, Brenner H, Habuchi T, Zhang HW, Lu YJ, Kaneva R, Muir K, Benlloch S, Leongamornlert DA, Saunders EJ, Tymrakiewicz M, Mahmud N, Guy M, O'Brien LT, Wilkinson RA, Hall AL, Sawyer EJ, Dadaev T, Morrison J, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Lophatonanon A, Southey MC, Hopper JL, English DR, Wahlfors T, Tammela TL, Klarskov P, Nordestgaard BG, Røder MA, Tybjærg-Hansen A, Bojesen SE, Travis R, Canzian F, Kaaks R, Wiklund F, Aly M, Lindstrom S, Diver WR, Gapstur S, Stern MC, Corral R, Virtamo J, Cox A, Haiman CA, Le Marchand L, Fitzgerald L, Kolb S, Kwon EM, Karyadi DM, Orntoft TF, Borre M, Meyer A, Serth J, Yeager M, Berndt SI, Marthick JR, Patterson B, Wokolorczyk D, Batra J, Lose F, McDonnell SK, Joshi AD, Shahabi A, Rinckleb AE, Ray A, Sellers TA, Lin HY, Stephenson RA, Farnham J, Muller H, Rothenbacher D, Tsuchiya N, Narita S, Cao GW, Slavov C, Mitev V, Easton DF, Eeles RA; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource; PRACTICAL Consortium.

Nat Genet. 2011 Jul 10;43(8):785-91. doi: 10.1038/ng.882.

22.

Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer.

FitzGerald LM, Kwon EM, Conomos MP, Kolb S, Holt SK, Levine D, Feng Z, Ostrander EA, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1196-203. doi: 10.1158/1055-9965.EPI-10-1299. Epub 2011 Apr 5.

23.

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk.

Kwon EM, Salinas CA, Kolb S, Fu R, Feng Z, Stanford JL, Ostrander EA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):923-33. doi: 10.1158/1055-9965.EPI-10-0994. Epub 2011 Mar 23.

24.

Genetic variation in RNASEL and risk for prostate cancer in a population-based case-control study.

Fesinmeyer MD, Kwon EM, Fu R, Ostrander EA, Stanford JL.

Prostate. 2011 Oct 1;71(14):1538-47. doi: 10.1002/pros.21370. Epub 2011 Feb 25.

25.

Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.

Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL, Mostaghel EA.

Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):619-27. doi: 10.1158/1055-9965.EPI-10-1023. Epub 2011 Jan 25.

26.

AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk.

Wright JL, Neuhouser ML, Lin DW, Kwon EM, Feng Z, Ostrander EA, Stanford JL.

Prostate. 2011 Apr;71(5):498-506. doi: 10.1002/pros.21267. Epub 2010 Oct 13.

27.

Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk.

Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL.

Am J Epidemiol. 2010 Sep 1;172(5):578-90. doi: 10.1093/aje/kwq175. Epub 2010 Aug 5.

28.

Vitamin D pathway gene variants and prostate cancer prognosis.

Holt SK, Kwon EM, Koopmeiners JS, Lin DW, Feng Z, Ostrander EA, Peters U, Stanford JL.

Prostate. 2010 Sep 15;70(13):1448-60. doi: 10.1002/pros.21180.

29.

CYP17 polymorphisms and prostate cancer outcomes.

Wright JL, Kwon EM, Lin DW, Kolb S, Koopmeiners JS, Feng Z, Ostrander EA, Stanford JL.

Prostate. 2010 Jul 1;70(10):1094-101. doi: 10.1002/pros.21143.

30.

Fine scale mapping of the breast cancer 16q12 locus.

Udler MS, Ahmed S, Healey CS, Meyer K, Struewing J, Maranian M, Kwon EM, Zhang J, Tyrer J, Karlins E, Platte R, Kalmyrzaev B, Dicks E, Field H, Maia AT, Prathalingam R, Teschendorff A, McArthur S, Doody DR, Luben R, Caldas C, Bernstein L, Kolonel LK, Henderson BE, Wu AH, Le Marchand L, Ursin G, Press MF, Lindblom A, Margolin S, Shen CY, Yang SL, Hsiung CN, Kang D, Yoo KY, Noh DY, Ahn SH, Malone KE, Haiman CA, Pharoah PD, Ponder BA, Ostrander EA, Easton DF, Dunning AM.

Hum Mol Genet. 2010 Jun 15;19(12):2507-15. doi: 10.1093/hmg/ddq122. Epub 2010 Mar 23.

31.

Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes.

Langeberg WJ, Tahir SA, Feng Z, Kwon EM, Ostrander EA, Thompson TC, Stanford JL.

Prostate. 2010 Jun 15;70(9):1020-35. doi: 10.1002/pros.21137.

32.

Association of hepsin gene variants with prostate cancer risk and prognosis.

Holt SK, Kwon EM, Lin DW, Ostrander EA, Stanford JL.

Prostate. 2010 Jun 15;70(9):1012-9. doi: 10.1002/pros.21135.

33.

Population-based study of the association of variants in mismatch repair genes with prostate cancer risk and outcomes.

Langeberg WJ, Kwon EM, Koopmeiners JS, Ostrander EA, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):258-64. doi: 10.1158/1055-9965.EPI-09-0800.

34.

Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study.

Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL.

Cancer Res. 2009 Dec 15;69(24):9315-22. doi: 10.1158/0008-5472.CAN-09-0648.

35.

Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study.

Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL.

Cancer Causes Control. 2010 Feb;21(2):289-300. doi: 10.1007/s10552-009-9461-5. Epub 2009 Nov 10.

36.

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study.

Eeles RA, Kote-Jarai Z, Al Olama AA, Giles GG, Guy M, Severi G, Muir K, Hopper JL, Henderson BE, Haiman CA, Schleutker J, Hamdy FC, Neal DE, Donovan JL, Stanford JL, Ostrander EA, Ingles SA, John EM, Thibodeau SN, Schaid D, Park JY, Spurdle A, Clements J, Dickinson JL, Maier C, Vogel W, Dörk T, Rebbeck TR, Cooney KA, Cannon-Albright L, Chappuis PO, Hutter P, Zeegers M, Kaneva R, Zhang HW, Lu YJ, Foulkes WD, English DR, Leongamornlert DA, Tymrakiewicz M, Morrison J, Ardern-Jones AT, Hall AL, O'Brien LT, Wilkinson RA, Saunders EJ, Page EC, Sawyer EJ, Edwards SM, Dearnaley DP, Horwich A, Huddart RA, Khoo VS, Parker CC, Van As N, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Cooper CS, Southey MC, Lophatananon A, Liu JF, Kolonel LN, Le Marchand L, Wahlfors T, Tammela TL, Auvinen A, Lewis SJ, Cox A, FitzGerald LM, Koopmeiners JS, Karyadi DM, Kwon EM, Stern MC, Corral R, Joshi AD, Shahabi A, McDonnell SK, Sellers TA, Pow-Sang J, Chambers S, Aitken J, Gardiner RA, Batra J, Kedda MA, Lose F, Polanowski A, Patterson B, Serth J, Meyer A, Luedeke M, Stefflova K, Ray AM, Lange EM, Farnham J, Khan H, Slavov C, Mitkova A, Cao G; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF.

Nat Genet. 2009 Oct;41(10):1116-21. doi: 10.1038/ng.450. Epub 2009 Sep 20.

37.

Vitamin D pathway gene variants and prostate cancer risk.

Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1929-33. doi: 10.1158/1055-9965.EPI-09-0113. Epub 2009 May 19.

38.

Analysis of recently identified prostate cancer susceptibility loci in a population-based study: associations with family history and clinical features.

Fitzgerald LM, Kwon EM, Koopmeiners JS, Salinas CA, Stanford JL, Ostrander EA.

Clin Cancer Res. 2009 May 1;15(9):3231-7. doi: 10.1158/1078-0432.CCR-08-2190. Epub 2009 Apr 14.

39.

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

Salinas CA, Koopmeiners JS, Kwon EM, FitzGerald L, Lin DW, Ostrander EA, Feng Z, Stanford JL.

Prostate. 2009 Mar 1;69(4):363-72. doi: 10.1002/pros.20887.

40.

Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

FitzGerald LM, Karlins E, Karyadi DM, Kwon EM, Koopmeiners JS, Stanford JL, Ostrander EA.

Prostate Cancer Prostatic Dis. 2009;12(2):192-7. doi: 10.1038/pcan.2008.46. Epub 2008 Sep 2.

41.

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer.

FitzGerald LM, Agalliu I, Johnson K, Miller MA, Kwon EM, Hurtado-Coll A, Fazli L, Rajput AB, Gleave ME, Cox ME, Ostrander EA, Stanford JL, Huntsman DG.

BMC Cancer. 2008 Aug 11;8:230. doi: 10.1186/1471-2407-8-230.

42.

Association of megalin genetic polymorphisms with prostate cancer risk and prognosis.

Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA.

Clin Cancer Res. 2008 Jun 15;14(12):3823-31. doi: 10.1158/1078-0432.CCR-07-4566.

43.

Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb.

Johanneson B, McDonnell SK, Karyadi DM, Hebbring SJ, Wang L, Deutsch K, McIntosh L, Kwon EM, Suuriniemi M, Stanford JL, Schaid DJ, Ostrander EA, Thibodeau SN.

Hum Genet. 2008 Feb;123(1):65-75. Epub 2007 Dec 8.

PMID:
18066601
44.

Antifungal cyclopeptolide from fungal saprophytic antagonist Ulocladium atrum.

Yun BS, Kwon EM, Kim JC, Yu SH.

J Microbiol Biotechnol. 2007 Jul;17(7):1217-20.

45.

Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer.

Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U.

Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1990-9.

46.

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer.

Agalliu I, Karlins E, Kwon EM, Iwasaki LM, Diamond A, Ostrander EA, Stanford JL.

Br J Cancer. 2007 Sep 17;97(6):826-31. Epub 2007 Aug 14.

47.

Suggestive genetic linkage to chromosome 11p11.2-q12.2 in hereditary prostate cancer families with primary kidney cancer.

Johanneson B, Deutsch K, McIntosh L, Friedrichsen-Karyadi DM, Janer M, Kwon EM, Iwasaki L, Hood L, Ostrander EA, Stanford JL.

Prostate. 2007 May 15;67(7):732-42.

PMID:
17372923
48.

Germline mutations in the BRCA2 gene and susceptibility to hereditary prostate cancer.

Agalliu I, Kwon EM, Zadory D, McIntosh L, Thompson J, Stanford JL, Ostrander EA.

Clin Cancer Res. 2007 Feb 1;13(3):839-43.

49.

Genetic susceptibility to aggressive prostate cancer.

Ostrander EA, Kwon EM, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1761-4. Review. No abstract available.

Supplemental Content

Support Center